Avacta Group Excellent data for the first clinical evaluation of lateral flow antigen test (Interview)

Avacta Group plc (LON:AVCT) CEO Alastair Smith joins DirectorsTalk to discuss first clinical evaluation of lateral flow antigen test. Alastair talks us through the data and explains the next steps in taking the test to market.

Find more news, interviews, share price & company profile here for:
Avacta Group Plc

Share this interview

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp
Avacta Group Excellent data for the first clinical evaluation of lateral flow antigen test (Interview)

Other Interviews

More News

Ask your questions

Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

I have questions